Abstracts tagged "population studies"

Abstract Number: 0014 • ACR Convergence 2020
Does the Type of Rheumatic Disease or Biologic Treatment Increase the Risk of Developing Severe COVID-19?
Fernando López-Gutierrez¹, Antía García-Fernández¹, Jesús Loarce-Martos¹, Laura Calvo-Sanz¹, Ivan Del Bosque-Granero², Veronica Garcia², Boris Blanco-Cáceres¹, Cristina Pijoan-Moratalla¹, Lourdes Villalobos-Sánchez³, Javier Bachiller-Corral¹ and Mónica Vázquez¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid
Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) have an increased risk for infection related to immunosuppression secondary to their disease, treatment and comorbidities. Nonetheless recent…
Abstract Number: 0562 • ACR Convergence 2020
The Relationship Between Heart Disease Risk Profile and Osteoarthritis, Overall and by Multi-/Single-Joint Involvement
Anthony Perruccio¹, Shatabdy Zahid², Calvin Yip³, J Denise Power², Mayilee Canizares², George Heckman⁴ and Elizabeth Badley¹, ¹Krembil Research Institute, UHN; University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Osteoarthritis (OA) and heart disease (HD) are among the most common chronic conditions. Several studies have shown that OA increases the risk of HD…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0566 • ACR Convergence 2020
Healthcare Utilization and Costs Prior to Diagnosis of ANCA Vasculitis in Medicare Beneficiaries
Shirley Huang¹, Xintong Li², Joehl Nguyen², Jacob Robinson², Susan Hogan³, Vimal Derebail³ and Carolyn Thorpe², ¹University of North Carolina at Chapel Hill, Chapel Hill, ²University of North Carolina Eshelman School of Pharmacy, Chapel Hill, ³University of North Carolina Kidney Center, Chapel Hill
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) vasculitis (AV) is a complex group of autoimmune disorders affecting blood vessels in multiple organ systems. Delays in diagnosis are…
Abstract Number: 058 • 2020 Pediatric Rheumatology Symposium
Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis
Cal Robinson ¹, Rahul Chanchlani ¹, Megan Schlorff ¹, Francis Lao ¹, Tapas Mondal ¹, Catherine Demers ¹, Elizabeth Darling ¹, Sandeep Brar ², Rulan Parekh ³, Hsien Seow ¹, Eric Benchimol ⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, Canada, ²University of California, San Fransisco, ³University of Toronto, Toronto, Canada, ⁴University of Ottawa, Ottawa, Canada
Background/Purpose: Kawasaki disease (KD) is a childhood vasculitis with rising global incidence and the most common cause of childhood acquired heart disease in the developed…
Abstract Number: 893 • 2019 ACR/ARP Annual Meeting
The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome
Petra Yntema-Eckenhaussen ¹, Suzanne Arends ¹, Elisabeth Brouwer ², Caroline Roozendaal ³, Hendrika Bootsma ⁴, Johanna Westra ¹ and Karina de Leeuw¹, ¹Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ⁴University of Groningen, Groningen, Netherlands
Background/Purpose: Previous studies have demonstrated that years before clinical onset of auto-immune diseases, auto-antibodies can already be present. However, it is also known that some…
Abstract Number: 2084 • 2019 ACR/ARP Annual Meeting
Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017
Kristina Theis¹, Michael Boring ² and Ross Wilkie ³, ¹Centers for Disease Control and Prevention, Atlanta, ²Johnson Consulting dba Cutting Edge Technologies and Solutions, Atlanta, ³Keele University, Keele, United Kingdom
Background/Purpose: “Arthritis-attributable activity limitation” (AAAL) is linked to many potentially modifiable characteristics (e.g., work disability, physical inactivity, obesity). By 2015, prevalence of AAAL among adults…
Abstract Number: 2189 • 2019 ACR/ARP Annual Meeting
Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
Marieke Loef¹, Féline PB Kroon ¹, Stephan Böhringer ¹, Frits R Rosendaal ¹ and Margreet Kloppenburg ¹, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire is a widely used patient-reported outcome tool, developed to evaluate short- and long-term knee symptoms…
Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Aladdin Mohammad¹, Pavlos Stamatis ¹ and Aleksandra Turkiewicz ², ¹Lund University, Lund, Skane Lan, Sweden, ²Lund University, Lund, Sweden
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…
Abstract Number: 1588 • 2018 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
Julia Tan¹, J. Antonio Avina-Zubieta², Alyssa Dominique³, Hamid Tavakoli⁴ and Teresa A Simon³, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic…
Abstract Number: 2417 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Systemic Lupus Erythematous and Pre-Systemic Lupus Erythematous: A Population-Based Cohort Study
A. Nicole Wade¹, Mary A. De Vera², Eric C. Sayre³ and J. Antonio Avina-Zubieta⁴, ¹Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada, Richmond, BC, Canada, ⁴Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The adverse effects of systemic lupus erythematosus (SLE) on maternal and fetal outcomes in pregnancy have been explored mainly in clinic-based cohorts. However, data…
Abstract Number: 2954 • 2018 ACR/ARHP Annual Meeting
Factors Related to Initiation of TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Angela Tong¹, Rishi J. Desai³ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: While efficacy of triple therapy [methotrexate (MTX), sulfasalazine (HCQ), and sulfasalazine (SSZ)] and TNF inhibitor (TNFi) plus MTX was similar in a previous clinical…
Abstract Number: 1957 • 2017 ACR/ARHP Annual Meeting
Impact of Maternal Systemic Autoimmune Rheumatic Diseases on Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of systemic autoimmune rheumatic diseases (SARDS) on peripartum outcomes is not well described at a population level despite the potential for active…
Abstract Number: 2651 • 2017 ACR/ARHP Annual Meeting
Association of ITGAM Polymorphism rs1143679 with Susceptibility to Systemic Lupus Erythematosus in North Indian Population
Sandeep Kumar¹, Vikas Gupta¹, Avadhesh Pratap², Rajeev Singh³, Reena Kumari³, Amita Aggarwal¹ and Ramnath Misra¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Biochemistry, King George Medical University, Lucknow, India
Background/Purpose: ITGAM (Integrin-α-M, also known as CD11b) gene located at chromosome 16p11.2, encodes for the α-chain of Integrin-αMβ2, a leucocyte specific integrin receptor, also known…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].